Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
1,2,4-benzothiadiazine derivatives useful for the treatment of endocrinological system diseases such as hyperinsulinaemia and diabetes. More
This invention relates to an animal model showing several behavioral and neuropathological features of schizophrenia. More
A number of specific PPLs, a group of prenylflavanone compounds, some novel, were isolated, identified and tested at as low as 0.04 μg/mL to be able to increase survival of neural stem cells, to promote neuronal growth with lengthening of neurite More
A non-transgenic, adult onset rodent model for Alzheimer's disease and stroke. More
Technology enable QD product opportunity available for out-license. More
Lotuzol is a new herbal drug composing water extract powder of Nelumbinis Semen to treat depression without sexual dysfunction, a major adverse effect in commonly used anti-depressants. More
A series of compounds with demonstrated anticonvulsant activity in mouse MES and scPTZ models, suggestive of broad spectrum anti-epileptic potential. More
A new method for screening for enantiomeric excess which is colorimetric, rapid and sensitive. More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Therapeutic target
- CNS trauma
- Diabetic neuropathy
- Fibromyalgia
- Muscular dystrophy
- Myasthenia gravis
- Peripheral neuropathy
- Sexual dysfunction
- Smoking cessation
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us